Identification of Biological and Pharmaceutical Mast Cell‐ and Basophil‐Related Targets

Mast Cells as Drivers of Disease and Therapeutic Targets

“…Therefore, blocking IgE-induced activation is not a suitable strategy for the treatment of all MC-driven diseases. At this point, no MC-specific drugs are available and there is a definite need for further research that identifies and defines unique MC-specific targets and molecules that can be used to engage them [66]. In addition, it is of great importance to further define predictive and prognostic biomarkers to monitor the effects of therapies on MC activation.…”